Mannoheptulose

08/01/1995 - "Rates of growth of human tumors in experimental animals are dramatically reduced (by 65-79%) by a dose of 1.7 mg/g mannoheptulose daily for 5 days. "
01/01/2020 - "We used D-Mannoheptulose, a specific hexokinase inhibitor, to inhibit glycolysis to enhance the Newcastle disease virus anti-tumor effect. "
08/01/1995 - "The potential of the naturally occurring sugar, mannoheptulose (which is purified from avocados and is assumed to be of low toxicity), as a cancer treatment is discussed."
08/01/1995 - "Mannoheptulose also causes inhibition of glucose uptake by tumor cells (25-75% at 30 mM mannoheptulose) and inhibition of rates of growth of cultured tumor cell lines (I50, 21.4 mM). "
11/01/1997 - "Further, utilizing D-mannoheptulose, a specific inhibitor of hepatic-/tumor-specific glucokinase, no dependence on the activity of this enzyme for growth or differentiation was observed. "

01/01/1976 - "Since administration of mannoheptulose induces temporary hyperglycemia, the present study was conducted to elucidate this phenomenon. "
12/01/1991 - "Ambrein did not reduce the hyperglycemia of glucose-loaded rats also given mannoheptulose but it reduced the hyperglycemia of glucose-loaded rats in the absence of mannoheptulose. "
09/01/1971 - "A striking rise in glucagon was observed despite accompanying hyperglycemia and hyperinsulinemia, which, in the case of mannoheptulose, was induced by infusing crystalline insulin. "
07/01/2009 - "In the first review on this issue, attention was already paid to various agents for labeling beta cells, including 6-(125)I-D-glucose, (65)Zn, (3)H-glibenclamide, (3)H-mitiglinide, an (125)I-labeled mouse monoclonal antibody against beta-cell surface ganglioside(s), D-(U-(14)C)-glucose and 2-deoxy-2-(18)F-D-glucose to label glycogen accumulated in beta cells in response to sustained hyperglycemia, and, last but not least, an analog of D-mannoheptulose. "
10/01/1979 - "PMB-induced hyperglycemia was abolished by pre-treatment with L-leucine and tolbutamide, but not by pre-treatment with D-mannoheptulose, or by post-treatment with insulin. "

03/01/1988 - "Effect of combined treatment of anti-inflammatory drug and mannoheptulose on the production of tumour necrosis factor and endotoxin shock in mice."
10/01/1987 - "Endotoxin shock and tumour necrosis factor release in mannoheptulose-treated mice."
03/31/1992 - "The endotoxin shock induced in mice during TNF production could be minimized by the combined administration of sulindac and mannoheptulose. "
03/01/1988 - "The endotoxin shock induced in mice by injection of viable Listeria monocytogenes and challenged with endotoxin can be alleviated by combined administration of mannoheptulose with acetylsalicylate or sulindac. "

03/01/1988 - "After acute pancreatectomy (P) or mannoheptulose treatment [0.14 mmole per 100 gm body weight (Group M)], similar cholestatic effects were observed (-0.29 and -0.27 microliter per min per gm liver, respectively). "
01/01/1976 - "Administration of mannoheptulose (MH) at a concentration of 200-300 mg./kg. body weight, administered intraperitoneally or intracardiacly resulted in a significant increase of plasma glucose concentration (24.3%) four hours after administration. "
09/01/1970 - "The rates of turnover of FFA, beta-hydroxybutyrate, and acetoacetate in rats fasted for 2 days were, respectively, 3.2, 5.6, and 2.5 mumoles/100 g body weight per min. Infusion of mannoheptulose with anti-insulin serum increased plasma glucose, FFA, and ketone body concentrations and decreased the specific activity of plasma FFA. "

03/01/1988 - "Effect of combined treatment of anti-inflammatory drug and mannoheptulose on the production of tumour necrosis factor and endotoxin shock in mice."
10/01/1987 - "Endotoxin shock and tumour necrosis factor release in mannoheptulose-treated mice."